New antibody trial aims to tame Sjögren's symptoms

NCT ID NCT07375524

Not yet recruiting Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests an experimental drug called ESG206 in 40 adults with primary Sjögren's syndrome, an autoimmune disease causing dry eyes and mouth. The drug targets a protein to reduce immune system attacks on the body. Researchers will compare high and low doses against a placebo to see if it safely controls disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ESG206 (a monoclonal antibody targeting BAFF-R)
What this could lead to: If successful, this could lead to a new treatment option that reduces disease activity and improves symptoms for people with Sjögren's syndrome.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SJÖGREN SYNDROME

Contacts and locations

Locations

Affiliated Hospital of Jining Medical University

Jining, Shandong, China
Affiliated Hospital of North Sichuan Medical College

Nanchong, Sichuan, China
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Changde First People's Hospital

Changde, Hunan, China
Hangzhou First People's Hospital

Hangzhou, Zhejiang, China
Hebei Petro China Central Hospital

Langfang, Hebei, China
Huzhou Third People's Hospital

Huzhou, Zhejiang, China
Jinhua Municipal Central Hospital

Jinhua, Zhejiang, China
Peking University Shougang Hospital

Beijing, Beijing Municipality, China
Pingxiang People's Hospital

Pingxiang, Jiangxi, China
Qilu Hospital of Shandong University

Jinan, Shandong, China
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China
Sichuan Provincial People's Hospital

Chengdu, Sichuan, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China
The Second Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China
Wenzhou People's Hospital

Wenzhou, Zhejiang, China
Xiangya Hospital of Central South University

Changsha, Hunan, China
Xuzhou Central Hospital

Xuzhou, Jiangsu, China
Zaozhuang Municipal Hospital

Zaozhuang, Shandong, China
Zhuzhou Central Hospital

Zhuzhou, Hunan, China
the Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.